Efficacy and Safety of Sodium Hyaluronate in the Treatment of Wilkes Stage II Disease

Oliveras-Moreno, Jose-Maria; Hernandez-Pacheco, Esther; Oliveras-Quintana, Teresa; Infante-Cossio, Pedro; Gutierrez-Perez, Jose-Luis

doi:10.1016/j.joms.2008.01.067

« Previous Next »Journal of Oral and Maxillofacial Surgery
Volume 66, Issue 11 , Pages 2243-2246, November 2008

Efficacy and Safety of Sodium Hyaluronate in the Treatment of Wilkes Stage II Disease

Jose-Maria Oliveras-Moreno, MD, DDS, PhD
- Staff Surgeon, Assistant Professor of Oral and Maxillofacial Surgery, Department of Oral and Maxillofacial Surgery, Virgen del Rocio University Hospital, Faculty of Dentistry, University of Seville, Seville, Spain
Esther Hernandez-Pacheco, MD, DDS, PhD
- Private Practice, Department of Oral and Maxillofacial Surgery, Virgen del Rocio University Hospital, Faculty of Dentistry, University of Seville, Seville, Spain
Teresa Oliveras-Quintana, DDS
- Private Practice, Department of Oral and Maxillofacial Surgery, Virgen del Rocio University Hospital, Faculty of Dentistry, University of Seville, Seville, Spain
Pedro Infante-Cossio, MD, DDS, PhD
- Staff Surgeon, Assistant Professor of Oral Surgery, Department of Oral and Maxillofacial Surgery, Virgen del Rocio University Hospital, Faculty of Dentistry, University of Seville, Seville, Spain
- Address correspondence and reprint requests to Dr Infante-Cossio: Department of Oral and Maxillofacial Surgery, Virgen del Rocio University Hospital, Manuel Siurot Av, 41013 Seville, Spain
Jose-Luis Gutierrez-Perez, MD, DDS, PhD
- Head, Professor of Oral Surgery, Department of Oral and Maxillofacial Surgery, Virgen del Rocio University Hospital, Faculty of Dentistry, University of Seville, Seville, Spain

Purpose

To show whether an intra-articular (IA) infiltration of 1 mL sodium hyaluronate (SH) into the temporomandibular joint (TMJ) would significantly reduce pain and improve joint function in Wilkes stage II disease, compared with the oral administration of a combination of methocarbamol and paracetamol.

Patients and Methods

Forty-one patients with Wilkes stage II disease were selected and randomly assigned to 2 groups. The experimental group received 1 IA infiltration of SH with assessments at days 14, 28, 56, and 84. The control group was given 2 tablets of a combination of methocarbamol 380 mg and paracetamol 300 mg every 6 hours for 4 weeks, with assessments at days 14 and 28.

Results

Forty-one patients were randomized into the study (SH: 20 patients, control drug: 21 patients). A statistically significant difference (P < . 05) was detected in favor of the SH group from day 56 onward for TMJ pain at rest, from day 14 onward for pain on jaw opening, and at days 28 and 56 for pain on mastication. The TMJ function was statistically significantly (P < .05) better in the test group at all follow-up visits. The global evaluation of efficacy by both, the patients and investigators, was better for the test group. No adverse reactions were detected with SH.

Conclusions

An IA infiltration of SH showed better efficacy in reducing pain and improving joint function in Wilkes stage II disease, compared with the oral administration of methocarbamol-paracetamol tablets.